For sale: one biotech, badly damaged. So starts what could be the final chapter in the story of Angion Biomedica. Weeks after halting a study over a potential safety signal, the biotech has decided to ...

In fact, the recent purchase by President Jay Venkatesan was not their only acquisition of Angion Biomedica shares this year. They previously made an even bigger purchase of US$730k worth of shares at ...

In a merger with troubled Angion Biomedica, Elicio Therapeutics has spied an opportunity to finally list on the Nasdaq as it prepares to push a cancer vaccine into phase 2 trials. The writing had been ...

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...

NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small ...

Angion Biomedica (ANGN) stock has had a difficult run since the company's shares leapt in initial trading after its IPO on Feb. 9, which raised $92m via the issuance of 5.75m shares at a price of $16.

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning catastrophes, wherever possible. We wouldn't blame Angion Biomedica Corp.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp ...

Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...

Elicio Therapeutics, a clinical-stage biotech, is merging with Angion Biomedica Corp to form a company that will focus on immunotherapies using Elicio’s proprietary lymph node-targeting Amphiphile ...